Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Recordati Ireland Limited, Raheens East, Ringaskiddy, Co. Cork, Ireland
Lercaril 20 mg/20 mg Film-coated Tablets.
Pharmaceutical Form |
---|
Film-coated tablet. Orange, circular, biconvex, tablets of 12 mm. |
Each film-coated tablet contains 20 mg enalapril maleate (equivalent to 15.29 mg enalapril) and 20 mg lercanidipine hydrochloride (equivalent to 18.88 mg lercanidipine).
Excipients with known effects: each tablet contains 204 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Enalapril |
Enalapril is hydrolysed via hepatic CES 1 to the active metabolite enalaprilat, which acts as an ACE inhibitor. ACE is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the vasoconstrictor substance angiotensin II and hence inhibition of ACE results in decreased plasma angiotensin II. This also leads to increased plasma renin activity and decreased aldosterone secretion. The mechanism of action of enalapril is therefore primarily via the suppression of the RAAS. However, ACE is identical to kininase II, and so enalapril may also exert its effects by blocking the degradation of bradykinin, a potent vasodepressor peptide. |
|
Enalapril and Lercanidipine |
Fixed combination of an ACE-inhibitor, enalapril, and a calcium channel blocker, lercanidipine, two antihypertensive compounds with complementary mechanism of action to control blood pressure in patients with essential hypertension. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. |
|
Lercanidipine |
Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance. |
List of Excipients |
---|
Core: Lactose monohydrate Film-Coating: Hypromellose 5 cP |
Polyamide-aluminium-PVC/aluminium blister.
Packs of 7, 14, 28, 30, 35, 42, 50, 56, 90, 98 and 100 tablets.
Not all pack sizes may be marketed.
Recordati Ireland Limited, Raheens East, Ringaskiddy, Co. Cork, Ireland
PA1404/002/003
Date of First Authorisation: 11th July 2014
Date of last renewal: 27th July 2016
Drug | Countries | |
---|---|---|
LERCARIL | Estonia, Ireland, Romania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.